Meibomian Gland Dysfunction Pipeline Update 2024: FDA Approvals, Therapeutic Advancements by DelveInsight | Novartis, Sentiss Pharma, RegeneRx, Akorn AFT Pharma, Alcon, Pfizer, AbbVie, Bausch Health

Posted on
by

Meibomian Gland Dysfunction Pipeline Update 2024: FDA Approvals, Therapeutic Advancements by DelveInsight | Novartis, Sentiss Pharma, RegeneRx, Akorn AFT Pharma, Alcon, Pfizer, AbbVie, Bausch Health
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Meibomian Gland Dysfunction pipeline constitutes 4+ key companies continuously working towards developing 4+ Meibomian Gland Dysfunction treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Meibomian Gland Dysfunction Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Meibomian Gland Dysfunction Market.

 

The Meibomian Gland Dysfunction Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Meibomian Gland Dysfunction Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Meibomian Gland Dysfunction treatment therapies with a considerable amount of success over the years. 

  • Meibomian Gland Dysfunction companies working in the treatment market are Laboratorios Thea, Tarsus Pharmaceuticals, and others, are developing therapies for the Meibomian Gland Dysfunction treatment 

  • Emerging Meibomian Gland Dysfunction therapies in the different phases of clinical trials are- Hydrocortisone Ophthalmic, Vehicle of TP-03, and others are expected to have a significant impact on the Meibomian Gland Dysfunction market in the coming years.   

  • In December 2023, Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new class of Ophthalmic Keratolytics for ocular surface diseases, announced positive topline efficacy and safety results from a Phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who struggled to wear their lenses comfortably and showed signs of Meibomian Gland Dysfunction (MGD). The trial successfully met its primary endpoint by demonstrating a statistically significant improvement in Meibomian Glands Yielding Liquid Secretion (MGYLS), indicated by the increased number of open glands.

 

Meibomian Gland Dysfunction Overview

Meibomian gland dysfunction (MGD) is a common eye condition where the meibomian glands, which are small oil-producing glands located in the eyelids, do not function properly. These glands secrete oils that form part of the tear film, which helps keep the eyes lubricated and protects them from drying out.

 

Get a Free Sample PDF Report to know more about Meibomian Gland Dysfunction Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight

 

Emerging Meibomian Gland Dysfunction Drugs Under Different Phases of Clinical Development Include:

  • Hydrocortisone Ophthalmic: Laboratorios Thea

  • Vehicle of TP-03: Tarsus Pharmaceuticals

 

Meibomian Gland Dysfunction Route of Administration

Meibomian Gland Dysfunction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

 

Meibomian Gland Dysfunction Molecule Type

Meibomian Gland Dysfunction Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy 

 

Meibomian Gland Dysfunction Pipeline Therapeutics Assessment

  • Meibomian Gland Dysfunction Assessment by Product Type

  • Meibomian Gland Dysfunction By Stage and Product Type

  • Meibomian Gland Dysfunction Assessment by Route of Administration

  • Meibomian Gland Dysfunction By Stage and Route of Administration

  • Meibomian Gland Dysfunction Assessment by Molecule Type

  • Meibomian Gland Dysfunction by Stage and Molecule Type

 

DelveInsight’s Meibomian Gland Dysfunction Report covers around 4+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I)

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

 

Further Meibomian Gland Dysfunction product details are provided in the report. Download the Meibomian Gland Dysfunction pipeline report to learn more about the emerging Meibomian Gland Dysfunction therapies

 

Some of the key companies in the Meibomian Gland Dysfunction Therapeutics Market include:

Key companies developing therapies for Meibomian Gland Dysfunction are – I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, Akorn, Inc. AFT Pharmaceuticals, Alcon Inc., Pfizer, Inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., Horus Pharma,  Mitotech, Novaliq GmbH, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, , Sun Pharmaceutical Industries Ltd, VISUfarma, and others.

 

Meibomian Gland Dysfunction Pipeline Analysis:

The Meibomian Gland Dysfunction pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Meibomian Gland Dysfunction with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Meibomian Gland Dysfunction Treatment.

  • Meibomian Gland Dysfunction key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Meibomian Gland Dysfunction Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Meibomian Gland Dysfunction market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Meibomian Gland Dysfunction drugs and therapies

 

Meibomian Gland Dysfunction Pipeline Market Strengths

  • Growing Incidence, Technological Advancements, Rising Awareness, Aging Population, Investment in Research, are some of the important factors that are fueling the Meibomian Gland Dysfunction Market.

 

Meibomian Gland Dysfunction Pipeline Market Opportunities

  • However, Complex Pathophysiology, Diagnostic Challenges, Competitive Landscape, Patient Compliance, and other factors are creating obstacles in the Meibomian Gland Dysfunction Market growth.

 

Scope of Meibomian Gland Dysfunction Pipeline Drug Insight    

  • Coverage: Global

  • Key Meibomian Gland Dysfunction Companies: Laboratorios Thea, Tarsus Pharmaceuticals, and others

  • Key Meibomian Gland Dysfunction Therapies: Hydrocortisone Ophthalmic, Vehicle of TP-03, and others

  • Meibomian Gland Dysfunction Therapeutic Assessment: Meibomian Gland Dysfunction current marketed and Meibomian Gland Dysfunction emerging therapies

  • Meibomian Gland Dysfunction Market Dynamics: Meibomian Gland Dysfunction market drivers and Meibomian Gland Dysfunction market barriers 

 

Request for Sample PDF Report for Meibomian Gland Dysfunction Pipeline Assessment and clinical trials

 

Table of Contents

1. Meibomian Gland Dysfunction Report Introduction

2. Meibomian Gland Dysfunction Executive Summary

3. Meibomian Gland Dysfunction Overview

4. Meibomian Gland Dysfunction- Analytical Perspective In-depth Commercial Assessment

5. Meibomian Gland Dysfunction Pipeline Therapeutics

6. Meibomian Gland Dysfunction Late Stage Products (Phase II/III)

7. Meibomian Gland Dysfunction Mid Stage Products (Phase II)

8. Meibomian Gland Dysfunction Early Stage Products (Phase I)

9. Meibomian Gland Dysfunction Preclinical Stage Products

10. Meibomian Gland Dysfunction Therapeutics Assessment

11. Meibomian Gland Dysfunction Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Meibomian Gland Dysfunction Key Companies

14. Meibomian Gland Dysfunction Key Products

15. Meibomian Gland Dysfunction Unmet Needs

16 . Meibomian Gland Dysfunction Market Drivers and Barriers

17. Meibomian Gland Dysfunction Future Perspectives and Conclusion

18. Meibomian Gland Dysfunction Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services